1,352 reports of this reaction
7.4% of all UMECLIDINIUM reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for UMECLIDINIUM, manufactured by GlaxoSmithKline LLC. There are 1,352 FDA adverse event reports linking UMECLIDINIUM to DYSPNOEA. This represents approximately 7.4% of all 18,218 adverse event reports for this drug.
Patients taking UMECLIDINIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among UMECLIDINIUM users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for UMECLIDINIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,352 FDA reports for UMECLIDINIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 7.4% of all adverse event reports for UMECLIDINIUM, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking UMECLIDINIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.